Thursday, 25 February 2021

Bosch invests in Emperra Digital Diabetes Care

05 January 2016 | News | By BioSpectrum Bureau

Bosch invests in Emperra Digital Diabetes Care

The funds will be used for further product development

The funds will be used for further product development

Emperra, a German start-up that has created a digital diabetes management solution consisting of smart hardware and software, has completed a Series B financing round of $3.1 million, with Robert Bosch Venture Capital GmbH (RBVC), a corporate venture capital company of the Bosch Group, joining the existing investors Peppermint Venture Partners and Investitionsbank des Landes Brandenburg. The funds will be used for further product development and to accelerate international growth, predominantly in the United States and Europe.

With its flagship product ESYSTA, Emperra has debuted the first ever fully integrated digital diabetes management system. In it, key innovations such as smart insulin pens (usable with all major insulin brands), wireless blood glucose meters, and CE-certified software work together seamlessly. The therapy data can be shared among all stakeholders (patient, physicians, nurses, care givers including relatives) and displayed via multiple channels, including a web-based portal, smart TV, and apps.

"ESYSTA provided us with compelling evidence of medical benefit in a study involving more than 200 patients," said Dr Dieter Kraft, an investment partner of Robert Bosch Venture Capital GmbH. "It was shown that mean glucose levels (measured as HbA1c) were significant lowered without increasing the potentially life-threatening risk of hypoglycemia".

ESYSTA has already received reimbursement status from German health insurers, which means ESYSTA hardware and software is now available on prescription for any patient with diabetes. Initial success in the German market confirms the effectiveness of this fully integrated diabetes care management.

"Digital health is poised to transform healthcare. With its data-driven therapy management, Emperra is excellently positioned to contribute to this transformation in the field of diabetes care," said Ms Gitte Bedford, vice president of Robert Bosch Venture Capital.

 

"Involving high-quality investors such as Bosch demonstrates the potential in our unique approach to diabetes care," said Dr Christian Krey, the CEO of Emperra. "In particular, having Bosch as a strategic investor means we have access to its global expertise in software automation, connected communities, and sensor technologies."

 

 

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account






Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls